drugset / Trial / NCT03166800
MitoQ for Fatigue in Multiple Sclerosis
Phase 1/2
Terminated
9 enrolled
Oregon Health and Science University
MitoQ Limited · collabNational Multiple Sclerosis Society · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after study drug initiation will assess if MitoQ has a significant change in fatigue.
Timeline
- Start
- 2018-09-15
- Primary completion
- 2019-01-10
- Completion
- 2019-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MitoQ | Small molecule | 20 mg | Oral |
| Comparator | MitoQ | Small molecule | 40 mg | Oral |